Life Sciences Tools and Services
Company Overview of Sarah Cannon Research Institute, LLC
Sarah Cannon Research Institute, LLC, a research organization, conducts clinical research programs in the United States. It conducts community-based clinical trials in oncology, cardiology, gastroenterology, internal medicine, pediatrics, obstetrics and gynecology, dermatology, allergy, and ENT. The company provides research site support services to its pharmaceutical and biotechnology partners, which include project management, data management and safety monitoring, oncology research, clinical monitoring, drug development, site qualification, regulatory, safety, quality assurance, medical writing, scientific analysis, and contracting and budget services, as well as biostatistics and site pa...
3322 West End Avenue
Nashville, TN 37203
Founded in 1993
Key Executives for Sarah Cannon Research Institute, LLC
Co-Founder and Principal Investigator of Sarah Cannon Research Institute
Chief Medical Officer and President of Clinical Operations
President of Scri Services
Compensation as of Fiscal Year 2016.
Sarah Cannon Research Institute, LLC Key Developments
Boehringer Ingelheim and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Immune-Oncology Therapies
Sep 29 16
Boehringer Ingelheim and Sarah Cannon Research Institute announced a new strategic collaboration. This partnership brings together Boehringer Ingelheim's extensive experience in cancer drug development and Sarah Cannon's expertise and leadership in designing and optimizing clinical trials. The partnership will help bring innovative cancer treatments to patients with unmet medical needs. The joint clinical development program will study Boehringer Ingelheim's BI 754091(anti- PD-1) and BI 754111 (anti-LAG 3) monoclonal antibodies for the combination treatment of multiple cancers with high unmet medical needs, including non-small cell lung cancer (NSCLC). BI 754091 and BI 754111 are immune checkpoint inhibitors designed to rally the patient's own immune system which is often suppressed by the tumor to fight cancer. As both compounds interact with the immune system at different points, the combination treatment approach is expected to result in better anti-tumor response, potentially leading to improved outcomes for patients. Following preliminary findings, the collaboration could be expanded beyond the initial research focus. Through Sarah Cannon Development Innovations, a full-service, oncology-focused contract research organization (CRO), Sarah Cannon will provide comprehensive clinical development services and operational delivery of Boehringer Ingelheim's early stage development programs. The collaboration will enable rapid patient enrollment to clinical trials through Sarah Cannon's extensive network across the U.S. and UK. Sarah Cannon is one of the world's leading clinical research organizations, conducting more than 220 first-in-human studies to date and enrolling more than 2,000 patients each year on innovative clinical trials.
Sarah Cannon and StafaCT, Inc. Announce Partnership in Developing New Technology for Comprehensive Electronic Blood and Marrow Transplantation
Feb 19 16
Sarah Cannon and StafaCT, Inc. announced their partnership in developing new technology for comprehensive electronic blood and marrow transplantation (BMT). Together, the partners created Stafa, a software focused on elevating patient care by managing the transplantation process and supporting the ability to monitor FACT compliance and process improvement. Across the industry, blood and marrow transplantation data has historically been recorded through paper documentation. In an effort to route patients and stem cell products seamlessly through the transplant process, Sarah Cannon Blood Cancer Network sought an electronic system. With the development of this software, Sarah Cannon’s BMT programs now have access to a comprehensive patient management software to track stem cell products from collection through infusion, and provide more effective long-term care management. Sarah Cannon Blood Cancer Network programs that have adopted the use of the software include: Texas Transplant Institute at Methodist Hospital in San Antonio, TX, St. David’s South Austin Medical Center in Austin, TX, and OU Medical Center in Oklahoma City, Okla. The remaining network programs will begin using the software by the end of 2016. Given the successful deployment and pilot results of the technology over the last three years, Sarah Cannon and StafaCT are working together to develop additional functionality and enhancements to the software. Plans include the design and integration of clinical pathways decision support and monitoring, post-transplant care management, as well as several other features to support compliance management.
Sarah Cannon, Hospital Corporation of America and StafaCT, Inc. Announce Partnership in Developing New Technology for Comprehensive Electronic Blood and Marrow Transplantation
Feb 19 16
Sarah Cannon, Hospital Corporation of America and StafaCT, Inc. announced their partnership in developing new technology for comprehensive electronic blood and marrow transplantation (BMT). Together, the partners created Stafa, a software focused on elevating patient care by managing the transplantation process and supporting the ability to monitor FACT compliance and process improvement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|